- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03670615
Using Exercise and Electrical Brain Stimulation to Improve Memory in Dementia (EXACT)
Exercise Augmenting Cognition tDCS (EXACT): A Pilot Study of a Combined Exercise and Transcranial Direct Current Stimulation Intervention for Cognition
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Objectives: To assess the efficacy of a combined exercise and tDCS treatment for improving cognitive outcomes in mild cognitive impairment and mild Alzheimer's disease.
Study Design: Eligible participants will be randomized to one of three interventions: Exercise and tDCS, Treatment as usual (TAU/exercise education) and tDCS, or Exercise and sham tDCS. Participants randomized to an exercise group will undergo exercise, followed by either sham or active tDCS. Participants randomized to TAU will receive written information in accordance with the Canadian Physical Activity Guidelines for older adults and tDCS for the same duration. Cognition, neuropsychiatric symptoms and blood samples for biomarker analysis will be collected.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Ella Song
- Phone Number: 63185 416-480-6100
- Email: bing.song@sri.utoronto.ca
Study Contact Backup
- Name: Mehreen Siddiqui
- Phone Number: 63185 416-480-6100
- Email: mehreen.siddiqui@sri.utoronto.ca
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M3H0A7
- Recruiting
- Sunnybrook Health Sciences Centre
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Males or females ≥50 years of age
- DSM-5 criteria for major or mild neurocognitive disorder due to AD or mixed AD/vascular disease
- Mild severity of impairment (standardized Mini-Mental State Examination (MMSE) score ≥19)
- Read and communicate in English
Exclusion Criteria:
- Change in cognitive enhancing medications (ChEIs and/or memantine) less than 3 months prior to study screen
- Change in anticonvulsants or psychotropic medications less than 1 month prior to study screen
- Currently taking benzodiazepines
- Presence of metal implants that would preclude safe use of tDCS (e.g. pace-maker)
- Significant neurological condition (e.g. epilepsy, Parkinson's disease, multiple sclerosis)
- Current psychiatric disorders (e.g. schizophrenia, bipolar disorder, depression, psychosis) or current substance use disorder
- Medical contraindications to increasing activity level according to the Canadian Society of Exercise Physiology Questionnaire
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Exercise and tDCS
Patients randomized to this group will attend Toronto Rehabilitation Institute - University Health Network (TRI-UHN) for an individualized exercise program and active tDCS intervention.
|
All study participants randomized to tDCS will receive active tDCS.
Participants will exercise at TRI according to an individualized exercise prescription.
|
Other: Exercise Education and tDCS
Patients randomized to this group will undergo treatment as usual, receiving routine advice about physical activity and active tDCS intervention.
|
All study participants randomized to tDCS will receive active tDCS.
Exercise education/ treatment as usual will include routine advice about physical activity for older adults.
Other Names:
|
Other: Exercise and Sham tDCS
Patients randomized to this group will attend TRI-UHN for an individualized exercise program and sham tDCS intervention.
|
Participants will exercise at TRI according to an individualized exercise prescription.
The same procedure for tDCS will be used for the sham condition, except without active current.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in cognition: The Word Recognition Task from the Alzheimer's Disease Assessment Scale Cog (ADAS-Cog)
Time Frame: Change over 2 weeks (Baseline to Endpoint)
|
Assess recognition memory.
Words incorrectly recognized will be tallied.
Word Recognition scores range from 0 to 12. Higher scores represent a worse outcome.
|
Change over 2 weeks (Baseline to Endpoint)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in cognition: n-back reaction time
Time Frame: Change over 2 weeks (Baseline to Endpoint)
|
A measure of working memory.
Reaction times in milliseconds will be recorded.
Higher values represent a worse outcome.
|
Change over 2 weeks (Baseline to Endpoint)
|
Change in cognition: The Word Recall Task from the Alzheimer's Disease Assessment Scale-Cog (ADAS-Cog)
Time Frame: Change over 2 weeks (Baseline to Endpoint)
|
Assesses recall memory.
Number of words not recalled will be tallied.
Word recall scores range from 0 to 10. Higher scores represent a worse outcome.
|
Change over 2 weeks (Baseline to Endpoint)
|
Change in global cognitive function: The Montreal Cognitive Assessment (MoCA) Total Scores
Time Frame: Change over 2 weeks Baseline to Endpoint
|
A brief measure of global cognition that includes assessments of orientation, short-term total memory, executive function, language abilities, attention and visuospatial ability.
MoCA scores range from 0 to 30.
Higher scores represent a better outcome.
|
Change over 2 weeks Baseline to Endpoint
|
Change in neuropsychiatric symptoms: The Neuropsychiatric Inventory (NPI)
Time Frame: Change over 2 weeks (Baseline to Endpoint)
|
A widely used assessment of behavior disturbances in dementia including: apathy, agitation, delusions, hallucinations, depression, euphoria, aberrant motor behavior, irritability, disinhibition, anxiety, sleeping, and eating.
Frequency and severity of each symptom is measured using subscales.
Frequency and severity are judged using a 4-point scale (ranging from 1-4) and 3-point scale (ranging from 1-3) respectively.
A 6-point scale for each symptom is used to evaluate caregiver distress (ranging from 0-5).
Higher values represent a worse outcome.
|
Change over 2 weeks (Baseline to Endpoint)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in concentration of blood biomarkers of brain plasticity
Time Frame: Change over 2 weeks (Baseline to Endpoint)
|
Biomarkers associated with exercise, tDCS outcomes, angiogenesis and neurogenesis will be obtained from blood work and analyzed using enzyme linked immunosorbent assays.
|
Change over 2 weeks (Baseline to Endpoint)
|
Collaborators and Investigators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 075-2018
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alzheimer Disease
-
ProgenaBiomeRecruitingAlzheimer Disease | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3 | Alzheimer Disease 4 | Alzheimer Disease 7 | Alzheimer Disease 17 | Alzheimer Disease 5 | Alzheimer Disease 6 | Alzheimer Disease 8 | Alzheimer Disease 10 | Alzheimer... and other conditionsUnited States
-
Cognito Therapeutics, Inc.RecruitingCognitive Impairment | Dementia | Alzheimer Disease | Mild Cognitive Impairment | Cognitive Decline | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | MCI | Dementia Alzheimers | Mild Dementia | Dementia of Alzheimer Type | Cognitive Impairment, Mild | Alzheimer Disease 1 | Dementia, Mild | Alzheimer... and other conditionsUnited States
-
AphiosNot yet recruitingDementia | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3
-
Capital Medical UniversityPeking University First Hospital; The First Affiliated Hospital of Anhui Medical... and other collaboratorsRecruitingAlzheimer Disease | Familial Alzheimer Disease (FAD)China
-
University of PennsylvaniaNational Institute on Aging (NIA)CompletedDementia | Alzheimer Disease, At Risk | Alzheimer Disease, Protection AgainstUnited States
-
Kyoto UniversityOsaka University; Mie University; Tokushima University; Tokyo Metropolitan Geriatric... and other collaboratorsCompletedFamilial Alzheimer Disease (FAD) | PSEN1 MutationJapan
-
University of ArizonaNational Institute on Aging (NIA); University of Southern California; Syneos... and other collaboratorsRecruitingNeurodegenerative Diseases | Alzheimer Dementia | Late Onset Alzheimer DiseaseUnited States
-
National Taiwan Normal UniversityCompletedAlzheimer Disease 2 Due to Apoe4 IsoformTaiwan
-
Northwell HealthRecruitingAlzheimer Disease | Alzheimer Disease With Delusions | Alzheimer Disease With PsychosisUnited States
-
University of Kansas Medical CenterNational Institute on Aging (NIA)CompletedHealthy Aging | Alzheimer Disease 2 Due to Apoe4 IsoformUnited States
Clinical Trials on tDCS
-
Hôpital le VinatierCompletedSchizophrenia | Auditory HallucinationsFrance, Tunisia
-
Universidad de AlmeriaSecretaría General de Universidades, Investigación y Tecnología, Junta de...Enrolling by invitationSubstance-Related DisordersSpain
-
Northeastern UniversityMassachusetts General Hospital; National Institute on Aging (NIA)Unknown
-
Nachum Soroker, MDUnknown
-
Bambino Gesù Hospital and Research InstituteCompleted
-
University of North Carolina, Chapel HillNational Institute of Mental Health (NIMH)CompletedMotor Activity | Motor NeuroplasticityUnited States
-
Charite University, Berlin, GermanyCompletedMigraine With Aura | CADASIL | Cerebral Microangiopathy | ICA StenosisGermany
-
Universidade Federal de PernambucoCompleted
-
Thorsten RudroffTerminatedMultiple Sclerosis | Neuropathic PainUnited States
-
University of MichiganNational Institute of Mental Health (NIMH)Completed